NCT05601037 LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema
| NCT ID | NCT05601037 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Ghent |
| Condition | Lymphedema, Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2021-06-30 |
| Primary Completion | 2025-12-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2021-06-30 with a primary completion date of 2025-12-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lymphedema is defined as a chronic condition, caused by lymphostasis. A major part in the Western world consists of iatrogenic lymphedema caused by surgery to the lymph nodes of the axilla or groin. Prophylactic lymphovenous anastomosis (LVA) could be beneficial in the prevention of lymphedema of the extremities.
Eligibility Criteria
Inclusion Criteria: * lymph node + breast cancer requiring dissection Exclusion Criteria: * previous lymphedema * BMI \>35
Contact & Investigator
Bernard Depypere, MD
PRINCIPAL INVESTIGATOR
UZ GENT
Frequently Asked Questions
Who can join the NCT05601037 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 99 Years, studying Lymphedema, Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05601037 currently recruiting?
Yes, NCT05601037 is actively recruiting participants. Contact the research team at bernard.depypere@ugent.be for enrollment information.
Where is the NCT05601037 trial being conducted?
This trial is being conducted at Ghent, Belgium.
Who is sponsoring the NCT05601037 clinical trial?
NCT05601037 is sponsored by University Hospital, Ghent. The principal investigator is Bernard Depypere, MD at UZ GENT. The trial plans to enroll 80 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.